ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zimberelimab

Also written as “Zimberelimab”, “GLS-010” and “AB122”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.

Drug pageZimberelimab: every studyMany companies study it; this page follows only the 20 they lead. All 51 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 19, 202220 company-led studies, 10 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou Gloria Biosciences74 open or runningphase 3since Aug 19, 2022Aug 28, 2018Dec 2026phase 2 · NCT05909436
Arcus Biosciencesits history only60 open or runningphase 3since Oct 3, 2022Jul 17, 2018none ahead
Gilead Sciencesits history only43 open or runningphase 3since Aug 12, 2022Apr 26, 2018Jun 2028phase 3 · NCT05502237
Otsukaits history only22 open or runningphase 3since Jul 3, 2026Jul 27, 2021Jun 2027phase 1 · NCT04999761
RemeGenits history only11 open or runningphase 2since Nov 23, 2023Nov 23, 2023Jun 30, 2027phase 2 · NCT06155396

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and Strata Oncology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Guangzhou Gloria Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2018First study: phase 2 study in Classical Hodgkin's LymphomaFirst studyNCT03655483 · 85 enrolled · China
  2. Sep 25, 2018Phase 1 study in Advanced Solid TumorsNCT03713905 · 293 enrolled · China
  3. May 31, 2019Phase 2 study in Uterine Cervical NeoplasmsNCT03972722 · 89 enrolled · China
  4. Jun 9, 2020Named zimberelimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, GLS-010, AB122
  5. Aug 19, 2022Phase 3 study in RecurrenceNCT05518318 · 60 planned
  6. Dec 26, 2022Phase 3 study in RecurrenceNCT05798819 · 424 planned · China
  7. May 4, 2023Phase 2 study in Solid TumorNCT05909436 · 107 planned · China
  8. Jul 26, 2023Phase 2 study in Advanced Non-Small Cell Lung CancerNCT05978401 · 152 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Solid TumorNCT05909436
  2. Dec 31, 2029Primary completion: phase 3 study in RecurrenceNCT05798819

TargetBeta

PDCD1 →read by rule
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 7 Guangzhou Gloria Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05978401Advanced Non-Small Cell Lung Cancer · China2Not yet recruitingApr 1, 2025152
NCT05909436Solid Tumor · China2RecruitingDec 2026107
NCT05798819Recurrence · China3RecruitingDec 31, 2029424
NCT05518318Recurrence3Not yet recruitingJun 202560
NCT03972722Uterine Cervical Neoplasms · China2UNKNOWNMay 15, 202289
NCT03713905Advanced Solid Tumors · China1CompletedFeb 28, 2022293
NCT03655483Classical Hodgkin's Lymphoma · China2UNKNOWNApr 11, 202185

How it is read

Names in the registry

  • “Zimberelimab”, 10 entries
  • “GLS-010”, 6 entries
  • “AB122”, 2 entries
  • “GLS-012+GLS-010”, 2 entries
  • “Zimberelimab (ZIM)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.